未经证实:严重的功能损害通常被认为是非肌层浸润性膀胱癌(NMIBC)膀胱内治疗的禁忌症。在患有严重功能障碍的高风险(HR)-NMIBC患者中评估了量身定制的膀胱内卡介苗(BCG)程序。
UNASSIGNED:Katz指数评分为2或以下且最初诊断为HR-NMIBC并无创伤插入Foley型留置导管的患者,膀胱排空,和卡介苗滴注进行前瞻性治疗;2小时后,排空膀胱并拔除导管(A组).在倾向得分匹配后,使用回顾性数据库将A组52例患者与B组52例连续患者进行比较,具有相似的基线/肿瘤特征,并采用标准间歇性导管插入术治疗。此外,A组和B组与130例连续患者(C组)进行回顾性评估,具有相似的肿瘤特征,但KatzIndex评分为3分或更高,并采用标准间歇性导管插入术治疗。
未经批准:停药率为11.5%,35%,A组9%,B,C,分别(A与B,对数等级得分42.52[p<0.05];Bvs.C,107.6[p<0.05];Avs.C,3.45[p>0.05])。总体不良事件发生率为38.5%,57.7%,和39.2%,分别(A与B,p=0.04;Bvs.C,0.03;Avs.C,0.92)。严重不良事件发生率为1.9%,1.9%,和1.5%,分别,没有统计学上的显著差异。HR累积无病生存率为63.4%,48%,和69.2%,分别(A与B,对数等级得分154.9[p<0.05];Bvs.C,415[p<0.05];Avs.C,244[p<0.05])。
UNASSIGNED:量身定制的膀胱内滴注程序可以减少卡介苗的停药和不良反应。
UNASSIGNED: Severe functional impairment is often considered a contraindication to intravesical therapy for nonmuscle-invasive bladder cancer (NMIBC). A tailored intravesical bacillus Calmette-Guérin (BCG) procedure was evaluated in high-risk (HR)-NMIBC patients with severe functional impairment.
UNASSIGNED: Patients with a Katz Index score of 2 or less and an initial diagnosis of HR-NMIBC with atraumatic insertion of a Foley-type indwelling catheter, bladder emptying, and BCG instillation were prospectively treated; after 2 hours, the bladder was emptied and the catheter was removed (group A).After propensity score matching, 52 patients in group A were compared with that of 52 consecutive patients in group B using a retrospective database, with similar baseline/oncological characteristics and treated with standard intermittent catheterization. Moreover, groups A and B were compared with that of 130 consecutive patients (group C) retrospectively evaluated, with similar oncological characteristics but with a Katz Index score of 3 or greater and treated with standard intermittent catheterization.
UNASSIGNED: The discontinuation rates were 11.5%, 35%, and 9% in groups A, B, and C, respectively (A vs. B, log-rank score 42.52 [p < 0.05]; B vs. C, 107.6 [p < 0.05]; A vs. C, 3.45 [p > 0.05]). The overall adverse event rates were 38.5%, 57.7%, and 39.2%, respectively (A vs. B, p = 0.04; B vs. C, 0.03; A vs. C, 0.92). The rates of severe adverse events were 1.9%, 1.9%, and 1.5%, respectively, without statistically significant differences. The cumulative HR disease-free survival rates were 63.4%, 48%, and 69.2%, respectively (A vs. B, log-rank score 154.9 [p < 0.05]; B vs. C, 415 [p < 0.05]; A vs. C, 244 [p < 0.05]).
UNASSIGNED: A tailored intravesical instillation procedure may reduce BCG discontinuation and adverse effects.